BTSA1
Based on 2 publication(s) in Google Scholar
BTSA1 is a potent, high affinity and orally active BAX activator with an IC50 of 250 nM and an EC50 of 144 nM. BTSA1 binds with high affinity and specificity to the N-terminal activation site and induces conformational changes to BAX leading to BAX-mediated apoptosis.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.77%
- No. CAS: 314761-14-3
- Fòrmula: C21H14N6OS2
- Peso molecular:430.51
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Orally Active Compound Library
HY-L061
-
Anti-Blood Cancer Compound Library
HY-L079
-
Mitochondria-Targeted Compound Library
HY-L089
-
Targeted Diversity Library
HY-L099
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Multi-Target Compound Library
HY-L176
-
Mitophagy Compound Library
HY-L180
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Apoptosis Compound Library
HY-L003
-
Anti-Cancer Compound Library
HY-L025
Publications Citing Use of MedChemExpress (MCE) BTSA1
More
Actividad biológica
|
Bax 250 nM (IC50) |
Bax 144 nM (EC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
>20 μM
Compound: 2; BTSA1
|
Antiproliferative activity against siRNA-induced BAX knock down human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against siRNA-induced BAX knock down human HeLa cells after 48 hrs by MTT assay
|
[PMID: 33021789] |
| HeLa | IC50 |
0.81 μM
Compound: 2; BTSA1
|
Synergistic antiproliferative activity against human HeLa cells assessed as assessed as reduction in cell viability after 48 hrs in presence of SAHA by MTT assay
Synergistic antiproliferative activity against human HeLa cells assessed as assessed as reduction in cell viability after 48 hrs in presence of SAHA by MTT assay
|
[PMID: 33021789] |
| HeLa | IC50 |
11.47 μM
Compound: 2; BTSA1
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 33021789] |
| L02 | IC50 |
54.2 μM
Compound: 2; BTSA1
|
Cytotoxicity against human L02 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 33021789] |
BTSA1 (5 μM; 6-24 hours; human AML cell lines) treatment reduced viability of all AML cell lines and displays substantial cell death activity within 6 hours[1].
BTSA1 (2.5-10 μM; 6 hours; NB4 cells) treatment induces BAX translocation coincided with the release of cytochrome c from the mitochondria to the cytosol. Significant BAX mitochondrial translocation is induced in a BTSA1 dose-dependent manner[1].
BTSA1 (0.15625-10 μM; 4-24 hours; OCI-AML3 cells) treatment induces dose-dependent caspase-3/7 activation in OCI-AML3 cells. Caspase-3/7 activation is monitored within 4-24 hours and maximal caspase-3/7 activation is detected in 4 hours[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human AML cell lines<
-
Concentration:5 μM
-
Incubation Time:6 hours, 12 hours, 24 hours
-
Result:Reduced viability of all AML cell lines. Displayed substantial cell death activity within 6 hours.
-
Cell Line:NB4 cells
-
Concentration:2.5 μM, 5 μM, 10 μM
-
Incubation Time:6 hours
-
Result:Significant BAX mitochondrial translocation was induced in a dose-dependent manner.
-
Cell Line:OCI-AML3 cells
-
Concentration:0.15625 μM, 0.3125 μM, 0.625 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM
-
Incubation Time:4 hours, 6 hours, 8 hours, 12 hours, 24 hours
-
Result:Induced dose-dependent caspase-3/7 activation in OCI-AML3 cells. Caspase-3/7 activation was monitored within 4-24 hr and maximal caspase-3/7 activation was detected in 4 hr.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD-SCID IL2Rγ null (NSG) mice (6-8 weeks old) with THP-1 cells[1]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection; every two days
-
Result:Significantly increased survival when compared to vehicle-treated mice.
Chemical Information
-
No. CAS 314761-14-3
-
Appearance Solid
-
Peso molecular 430.51
-
Fòrmula C21H14N6OS2
-
Color Brown to reddish brown
-
SMILES
O=C(N(C1=NC(C2=CC=CC=C2)=CS1)N=C/3C4=CC=CC=C4)C3=N\NC5=NC=CS5
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Eur J Pharmacol
Characterization of mitochondrial dysfunction induced by BAX trigger site activator 1 in the ARPE-19 retinal pigment epithelial cell model. [Abstract]2026 Jun 15:1027:178975. PMID: 42134759 -
Int J Mol Sci
Mitochondrial Trafficking of MLKL, Bak/Bax, and Drp1 Is Mediated by RIP1 and ROS which Leads to Decreased Mitochondrial Membrane Integrity during the Hyperglycemic Shift to Necroptosis. [Abstract]2023 May 11;24(10):8609. PMID: 37239951
Solvente y solubilidad
DMSO : 25 mg/mL (58.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureza y Documentación
-
Ficha de datos (280 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3228 mL | 11.6141 mL | 23.2283 mL | 58.0707 mL |
| 5 mM | 0.4646 mL | 2.3228 mL | 4.6457 mL | 11.6141 mL | |
| 10 mM | 0.2323 mL | 1.1614 mL | 2.3228 mL | 5.8071 mL | |
| 15 mM | 0.1549 mL | 0.7743 mL | 1.5486 mL | 3.8714 mL | |
| 20 mM | 0.1161 mL | 0.5807 mL | 1.1614 mL | 2.9035 mL | |
| 25 mM | 0.0929 mL | 0.4646 mL | 0.9291 mL | 2.3228 mL | |
| 30 mM | 0.0774 mL | 0.3871 mL | 0.7743 mL | 1.9357 mL | |
| 40 mM | 0.0581 mL | 0.2904 mL | 0.5807 mL | 1.4518 mL | |
| 50 mM | 0.0465 mL | 0.2323 mL | 0.4646 mL | 1.1614 mL |
BTSA1 Related Classifications
HY-123054 Related Classifications
Powered by Bioz